Joanne Tobacman

Dr. Joanne Tobacman

Department of Medicine, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SBSumit Bhattacharyya
Sumit Bhattacharyya
RGRavinder Gill
Ravinder Gill
MCMei Ling Chen
Mei Ling Chen
FZFuming Zhang
Fuming Zhang
RLRobert J. Linhardt
Robert J. Linhardt
JTJoanne Tobacman
Joanne Tobacman
The sulfated polysaccharide carrageenan (CGN) induces activation of NFκB and interleukin 8 (IL-8) in human colonic epithelial cells through a pathway of innate immunity mediated by Bcl10 (B-cell CLL/lymphoma 10). In this report, we identify Toll-like receptor 4 (TLR4), a member of the family of innate immune receptors, as the surface membrane receptor for CGN in human colonic epithelial cells. Experiments with fluorescence-tagged CGN demonstrated a marked reduction in binding of CGN to human intestinal epithelial cells and to RAW 264.7 mouse macrophages, following exposure to TLR4 blocking antibody (HTA-125). Binding of CGN to 10ScNCr/23 mouse macrophages, which are deficient in the genetic locus for TLR4, was absent. Additional experiments with TLR4 blocking antibody and TLR4 small interfering RNAs showed 80% reductions in CGN-induced increases in Bcl10 and IL-8. Transfection with dominant-negative MyD88 plasmid demonstrated MyD88 dependence of the CGN-TLR4-triggered increases in Bcl10 and IL-8. Therefore, these results indicate that CGN-induced inflammation in human colonocytes proceeds through a pathway of innate immunity, perhaps related to the unusual α-1,3-galactosidic linkage characteristic of CGN, and suggest how dietary CGN intake may contribute to human intestinal inflammation. Because CGN is a commonly used food additive in the Western diet, clarification of its effects and mechanisms of action are vital to issues of food safety.

1 March 2007 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
ABAlip Borthakur
Alip Borthakur
SBSumit Bhattacharyya
Sumit Bhattacharyya
PDPradeep K. Dudeja
Pradeep K. Dudeja
JTJoanne Tobacman
Joanne Tobacman
Carrageenan is a high molecular weight sulfated polygalactan used to improve the texture of commercial food products. Its use increased markedly during the last half century, although carrageenan is known to induce inflammation in rheumatological models and in intestinal models of colitis. We performed studies to determine its direct effects on human intestinal cells, including normal human intestinal epithelial cells from colonic surgeries, the normal intestinal epithelial cell line NCM460, and normal rat ileal epithelial cells. Cells were treated with high molecular weight λ-carrageenan at a concentration of 1 μg/ml for 1–96 h. IL-8, IL-8 promoter activity, total and nuclear NF-κB, IκBα, phospho-IκBα, and Bcl10 were assessed by immunohistochemistry, Western blot, ELISA, and cDNA microarray. Increased Bcl10, nuclear and cytoplasmic NF-κB, IL-8 promoter activation, and IL-8 secretion were detected following carrageenan exposure. Knockdown of Bcl10 by siRNA markedly reduced the increase in IL-8 that followed carrageenan exposure in the NCM460 cells. These results show, for the first time, that exposure of human intestinal epithelial cells to carrageenan triggers a distinct inflammatory pathway via activation of Bcl10 with NF-κB activation and upregulation of IL-8 secretion. Since Bcl10 contains a caspase-recruitment domain, similar to that found in NOD2/CARD15 and associated with genetic predisposition to Crohn's disease, the study findings may represent a link between genetic and environmental etiologies of inflammatory bowel disease. Because of the high use of carrageenan as a food additive in the diet, the findings may have clinical significance.

30 March 2017 in Nutrition and Healthy Aging
Verified
Journal Article
Open access
PDF file
SBSumit Bhattacharyya
Sumit Bhattacharyya
TSTheresa Shumard
Theresa Shumard
HXHui Xie
Hui Xie
ADAmar Dodda
Amar Dodda
KVKrista A. Varady
Krista A. Varady
JTJoanne Tobacman
Joanne Tobacman
BACKGROUND: Carrageenan is a very common food additive in Western diets, but predictably causes inflammation in thousands of cell-based and animal experiments. OBJECTIVE: To assess the impact of carrageenan exposure on the interval to relapse in patients with ulcerative colitis in remission. METHODS: A randomized, double-blind, placebo-controlled, multicenter, clinical trial was conducted to assess if patients with ulcerative colitis in remission would have a longer interval to relapse if they followed a diet with no carrageenan. All participants were instructed in the no-carrageenan diet and were randomized to either placebo capsules or carrageenan-containing capsules. The carrageenan in the capsules was less than the average daily carrageenan intake from the diet. Relapse was defined as an increase of two or more points on the Simple Clinical Colitis Activity Index (SCCAI) and intensification of treatment for ulcerative colitis. Participants were followed by telephone calls every two weeks until relapse or one year of participation. The occurrence of relapse and inflammatory biomarkers were compared between the two groups. RESULTS: Twelve patients completed study questionnaires. Three patients who received carrageenan-containing capsules relapsed, and none of the patients who received placebo-containing capsules relapsed ( p = 0.046, log-rank test). Laboratory tests showed increases in Interleukin-6 ( p = 0.02, paired t-test, two-tailed) and fecal calprotectin ( p = 0.06; paired t-test, two-tailed) between the beginning and the end of study participation in the carrageenan-exposed group, but not in the placebo-group. CONCLUSION: Carrageenan intake contributed to earlier relapse in patients with ulcerative colitis in remission. Restriction of dietary carrageenan may benefit patients with ulcerative colitis.

1 October 2010 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
SBSumit Bhattacharyya
Sumit Bhattacharyya
HLHaiying Liu
Haiying Liu
ZZZhenqing Zhang
Zhenqing Zhang
MJMurielle Jam
Murielle Jam
PDPradeep K. Dudeja
Pradeep K. Dudeja
JTJoanne Tobacman
Joanne Tobacman

20 October 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SBS. Bhattacharyya
S. Bhattacharyya
IOInSug O-Sullivan
InSug O-Sullivan
SKS. Katyal
S. Katyal
TUT. Unterman
T. Unterman
JTJoanne Tobacman
Joanne Tobacman

1 March 2008 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
SBSumit Bhattacharyya
Sumit Bhattacharyya
ABAlip Borthakur
Alip Borthakur
PDPradeep K. Dudeja
Pradeep K. Dudeja
JTJoanne Tobacman
Joanne Tobacman
Multiple studies in animal models have shown that the commonly used food additive carrageenan (CGN) induces inflammation and intestinal neoplasia. We performed the first studies to determine the effects of CGN exposure on human intestinal epithelial cells (IEC) in tissue culture and tested the effect of very low concentrations (1–10 mg/L) of undegraded, high-molecular weight CGN. These concentrations of CGN are less than the anticipated exposure of the human colon to CGN from the average Western diet. In the human colonic epithelial cell line NCM460 and in primary human colonic epithelial cells that were exposed to CGN for 1–8 d, we found increased cell death, reduced cell proliferation, and cell cycle arrest compared with unexposed control cells. After 6–8 d of CGN exposure, the percentage of cells reentering G0-G1 significantly decreased and the percentages of cells in S and G2-M phases significantly increased. Increases in activated p53, p21, and p15 followed CGN exposure, consistent with CGN-induced cell cycle arrest. Additional data, including DNA ladder, poly ADP ribose polymerase Western blot, nuclear DNA staining, and activities of caspases 3 and 7, indicated no evidence of increased apoptosis following CGN exposure and were consistent with CGN-induced necrotic cell death. These data document for the first time, to our knowledge, marked adverse effects of low concentrations of CGN on survival of normal human IEC and suggest that CGN exposure may have a role in development of human intestinal pathology.